MX2011010616A - Metodos para tratar edema relacionado a isquemia-reperfusion. - Google Patents

Metodos para tratar edema relacionado a isquemia-reperfusion.

Info

Publication number
MX2011010616A
MX2011010616A MX2011010616A MX2011010616A MX2011010616A MX 2011010616 A MX2011010616 A MX 2011010616A MX 2011010616 A MX2011010616 A MX 2011010616A MX 2011010616 A MX2011010616 A MX 2011010616A MX 2011010616 A MX2011010616 A MX 2011010616A
Authority
MX
Mexico
Prior art keywords
reperfusion
methods
isemaem
edem
treat
Prior art date
Application number
MX2011010616A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Michael Egan
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Publication of MX2011010616A publication Critical patent/MX2011010616A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2011010616A 2009-04-09 2010-04-09 Metodos para tratar edema relacionado a isquemia-reperfusion. MX2011010616A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16808909P 2009-04-09 2009-04-09
PCT/US2010/030556 WO2010118334A1 (en) 2009-04-09 2010-04-09 Methods of treating edema related to ischemia-reperfusion

Publications (1)

Publication Number Publication Date
MX2011010616A true MX2011010616A (es) 2012-03-14

Family

ID=42936599

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011010616A MX2011010616A (es) 2009-04-09 2010-04-09 Metodos para tratar edema relacionado a isquemia-reperfusion.

Country Status (14)

Country Link
US (1) US20120064044A1 (cg-RX-API-DMAC7.html)
EP (1) EP2416651A4 (cg-RX-API-DMAC7.html)
JP (1) JP2012523432A (cg-RX-API-DMAC7.html)
KR (1) KR20120005025A (cg-RX-API-DMAC7.html)
CN (1) CN102458113A (cg-RX-API-DMAC7.html)
AU (1) AU2010233151A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI1010516A2 (cg-RX-API-DMAC7.html)
CA (1) CA2757998A1 (cg-RX-API-DMAC7.html)
EA (1) EA201101349A1 (cg-RX-API-DMAC7.html)
IL (1) IL215604A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011010616A (cg-RX-API-DMAC7.html)
SG (1) SG175133A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010118334A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201107815B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126822A2 (en) 2008-04-09 2009-10-15 The University Of North Carolina At Chapel Hill Methods of regulating actin cytoskeletal rearrangement and intercellular gap formation
EP2681314B1 (en) 2011-03-03 2017-11-01 Quark Pharmaceuticals, Inc. Compositions and methods for treating lung disease and injury
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
WO2018165656A1 (en) 2017-03-10 2018-09-13 The University Of North Carolina At Chapel Hill Short-acting heparin-based anticoagulant compounds and methods
US11993627B2 (en) 2017-07-03 2024-05-28 The University Of North Carolina At Chapel Hill Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides
US11865137B2 (en) 2017-11-03 2024-01-09 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
BR112020016314A2 (pt) 2018-02-12 2020-12-15 Inimmune Corporation Compostos ou um sais farmaceuticamente aceitáveis, composição farmacêutica, kit, e, métodos para elicitar, intensificar ou modificar uma resposta imunológica, para tratar, prevenir ou reduzir a suscetibilidade a câncer, para tratar, prevenir ou reduzir a suscetibilidade a uma doença infecciosa, para tratar, prevenir ou reduzir a suscetibilidade a uma alergia, para tratar, prevenir ou reduzir a suscetibilidade a uma afecção autoimune, para tratar, prevenir ou reduzir a suscetibilidade em um sujeito à infecção bacteriana, viral, priônica, autoimunidade, câncer ou alergia, para tratar, prevenir ou reduzir a suscetibilidade à autoimunidade, alergia, reperfusão de isquemia ou sepse, para tratar, prevenir ou reduzir a gravidade de ataques epiléticos e para tratar, prevenir ou reduzir a suscetibilidade a doenças oculares como degeneração macular, hipertensão ocular e infecção ocular
WO2019246264A1 (en) 2018-06-20 2019-12-26 The University Of North Carolina At Chapel Hill Cell protective methods and compositions
WO2021097345A1 (en) * 2019-11-13 2021-05-20 The University Of North Carolina At Chapel Hill Heparan sulfate (hs) oligosaccharides effect in liver ischemia reperfusion injury

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05139992A (ja) * 1991-11-13 1993-06-08 Ajinomoto Co Inc ヒトadfを含有する臓器保護剤
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US7960522B2 (en) * 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
WO2004085396A1 (ja) * 2003-03-26 2004-10-07 Mitsubishi Pharma Corporation 虚血再灌流障害の予防または治療剤、臓器保存剤およびスクリーニング方法
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US7928132B2 (en) * 2004-08-06 2011-04-19 Ohio University Methods for the amelioration of episodes of acute or chronic ulcerative colitis
AU2008285626B2 (en) * 2007-08-03 2013-09-12 Neuramedy Co., Ltd. Use of TLR-2 antagonists for treatment of reperfusion injury and tissue damage
WO2009126822A2 (en) * 2008-04-09 2009-10-15 The University Of North Carolina At Chapel Hill Methods of regulating actin cytoskeletal rearrangement and intercellular gap formation

Also Published As

Publication number Publication date
KR20120005025A (ko) 2012-01-13
AU2010233151A1 (en) 2011-11-17
BRPI1010516A2 (pt) 2015-08-25
EA201101349A1 (ru) 2012-05-30
EP2416651A1 (en) 2012-02-15
CA2757998A1 (en) 2010-10-14
US20120064044A1 (en) 2012-03-15
WO2010118334A1 (en) 2010-10-14
JP2012523432A (ja) 2012-10-04
EP2416651A4 (en) 2014-03-26
SG175133A1 (en) 2011-12-29
ZA201107815B (en) 2013-04-24
IL215604A0 (en) 2011-12-29
CN102458113A (zh) 2012-05-16

Similar Documents

Publication Publication Date Title
CR20110560A (es) Métodos de tratamiento para tumores sólidos
CR20110686A (es) Pirimidinonas como ihnibidores de pi3k
UY33627A (es) Compuestos para tratar enfermedades neurodegenerativas
DOP2011000009A (es) Amidofenoxiindazoles utiles como inhibidores de c-met
ECSP12012230A (es) Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
PA8841901A1 (es) Compuestos orgánicos
NI201500088A (es) Inhibidores de histona desmetilasa
GT200800202A (es) Quinazolinas para la inhibicion de pdk1
BR112012019302A2 (pt) imidazo[1,2-b][1,2,4]triazinas como inibidores de c-met
CR11485A (es) Tratamiento de cancer de mama con un inhibidor de parp solo o en combinacion con agentes anti-tumorales
HN2007015177A (es) Derivados de triazolopirazina
MX2010009765A (es) Moleculas pequeñas que contienen boro como agentes anti-inflamatorios.
CR20170071A (es) Compuestos terapeuticos y composiciones
CR20110326A (es) Compuestos pirazina como inhibidores de fosfodiesterasa 10
BRPI1000320B8 (pt) Composições e métodos para tratar sinais de envelhecimento da pele
CR11870A (es) Composiciones de perácido y 2-hidroxi ácido orgánico y métodos para tratar productos agrícolas
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
CO2019000753A2 (es) Métodos para tratar el cáncer de próstata
EA201101349A1 (ru) Методы лечения отека, связанного с ишемией-реперфузией
MX2012007032A (es) Composiciones organicas para tratar las enfermedades relacionadas con hsf1.
EA201170294A1 (ru) Способы лечения реперфузионных повреждений
UY34466A (es) Proceso para estabilizar contenido bacteriano de treparaciones minerales acuosas que comprenden carbbonatos de calcio.
GT201200345A (es) Compuestos heterocìclicos, su preparaciòn y su aplicaciòn terapèutica
BR112013012858A2 (pt) anticorpos que se ligam a pectina acetilesterase de notum

Legal Events

Date Code Title Description
FA Abandonment or withdrawal